| The effects of zoledronic acid on serum lipids in multiple myeloma patients. | |
| | |
MedLine Citation:
|
PMID: 18418538 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nitrogen-containing bisphosphonates (N-BPs) inhibit osteoclast-mediated bone resorption and are widely used for tumor-associated osteolysis. The mechanism of action of these drugs has not been completely clarified, but it has been observed that N-BPs may inhibit squalene synthase or farnesyl pyrophosphate synthase. Zoledronic acid (ZA) represents a novel N-BP which also has antitumor activity. To explore the effects of ZA on serum lipids, we studied 26 patients with smoldering myeloma at diagnosis. Sixteen patients were treated with ZA (4 mg) at baseline and at months 1, 2, 4, and 6. The remaining 10 served as controls. In all subjects, total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and C-terminal telopeptide of type I collagen (CTX) were measured at baseline and after 1, 3, and 6 months. In treated patients, we observed a progressive and significant reduction of TC, with a maximum decrease of 13% at 6 months. Moreover LDL-C decreased by 21% at 6 months, while no significant difference was appreciated in HDL-C and TGs. Also, the indexes of cardiovascular risk improved after ZA administration: TC/HDL-C ratio progressively decreased by 17% and HDL-C/LDL-C ratio increased by 36%, showing an effect that appears to be cumulative. In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index. |
| | |
Authors:
|
Alessandro Gozzetti; Luigi Gennari; Daniela Merlotti; Stefania Salvadori; Vincenzo De Paola; Annalisa Avanzati; Beatrice Franci; Elena Marchini; Monica Tozzi; Maria Stella Campagna; Ranuccio Nuti; Francesco Lauria; Giuseppe Martini |
Related Documents
:
|
12862308 - Effects of diet treatment on some biochemical and physiological parameters in patients ... 21539488 - Diet and alzheimer's disease risk factors or prevention: the current evidence. 3152618 - Effects of glyburide treatment on serum lipoprotein and apolipoprotein concentrations a... 7611158 - Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for ... 2159098 - The effect of alfalfa-corn diets on cholesterol metabolism and gallstones in prairie dogs. 22075268 - Modest reversal of metabolic syndrome manifestations with vitamin d status correction: ... |
Publication Detail:
|
Type: Journal Article Date: 2008-04-17 |
Journal Detail:
|
Title: Calcified tissue international Volume: 82 ISSN: 0171-967X ISO Abbreviation: Calcif. Tissue Int. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-05-01 Completed Date: 2008-07-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7905481 Medline TA: Calcif Tissue Int Country: United States |
Other Details:
|
Languages: eng Pagination: 258-62 Citation Subset: IM |
Affiliation:
|
Division of Hematology and Transplants, Policlinico "Santa Maria Le Scotte", University of Siena, Siena 53100, Italy. gozzetti@unisi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Atherosclerosis / metabolism Bone Density Conservation Agents / therapeutic use Cholesterol, HDL / metabolism Collagen / chemistry Diphosphonates / chemistry, pharmacology* Female Humans Imidazoles / pharmacology* Lipids / chemistry Male Middle Aged Multiple Myeloma / blood*, drug therapy* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Cholesterol, HDL; 0/Diphosphonates; 0/Imidazoles; 0/Lipids; 118072-93-8/zoledronic acid; 9007-34-5/Collagen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Severe bleeding from internal obturator muscle following tension-free vaginal tape Secur hammock app...
Next Document: Block of persistent late Na+ currents by antidepressant sertraline and paroxetine.